NCT02147925View on ClinicalTrials.gov

Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Liraglutide combined with metformin

Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week

DRUG

Insulin glargine combined with metformin

The initial dose will be 0.2 unit/kg/d

DRUG

Sitagliptin combined with metformin

The dose throughout the study will be 100mg per day.

Trial Locations (1)

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02147925 - Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects | Biotech Hunter | Biotech Hunter